Net sales of ¥42.5 billion and operating margin of 15% or higher for the fiscal year ending September 2019
First written in FY2017. 1 of 4 entries say "Restated". Latest entry: FY2020.
Fuji Pharma moved to the "Worse" side of this theme in 2020, 2 years before the typical company in this theme (2022).
The whole theme swung hardest in 2019: 14 of 100 companies on the "Worse" side.
19 other companies' latest entry also says "Reframed".
- FY2020ReframedAnnual report
「For the fiscal year ending September 2024, the final year of the medium-term management plan, we aim to achieve revenue of ¥50.0 billion, operating profit of ¥5.0 billion and return on equity (ROE) of 8.0%.」
Following the failure to achieve the targets of the previous medium-term management plan, whose final year was the fiscal year ending September 2019, the plan has changed to new numerical targets for the fiscal year ending September 2024. - FY2019Target not achievedAnnual report
「However, although the target for the final year, the fiscal year ending September 2019, was consolidated revenue of ¥42.5 billion and consolidated operating profit of ¥6.7 billion, actual results were consolidated revenue of ¥36.2 billion and consolidated operating profit of ¥4.1 billion.」
For the final year of the five-year medium-term management plan, actual results were ¥36.2 billion in consolidated revenue and ¥4.1 billion in consolidated operating profit, versus targets of ¥42.5 billion and ¥6.7 billion, respectively. - FY2018RestatedAnnual report
「Under the Group's five-year medium-term management plan, which began in the fiscal year ending September 2015, we are working toward revenue of ¥42.5 billion and an operating margin of 15% or higher in the final year of the plan. In the fourth year, the current consolidated fiscal year, revenue was ¥37,909 million, up 7.1% year on year, and the operating margin was 11.6%, down 0.6 percentage points from the previous consolidated fiscal year. For the fiscal year ending September 2019, revenue is expected to be ¥36,815 million and operating profit ¥4,535 million. We will continue working to improve these metrics.」
The final targets of ¥42.5 billion in revenue and an operating margin of 15% or higher remain unchanged. Progress disclosed to date shows fourth-year revenue of ¥37.909 billion and an operating margin of 11.6%, with revenue of ¥36.815 billion and operating profit of ¥4.535 billion expected for the fiscal year ending September 2019. - FY2017First statedAnnual report
「Under the Group's five-year medium-term management plan, which began in the fiscal year ending September 2015, we are working toward revenue of ¥42.5 billion and an operating margin of 15% or higher in the fiscal year ending September 2019, the final year of the plan.」
For the first time, creates a thread on the numerical targets for revenue and operating margin toward the final year of the five-year medium-term management plan.